Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease

Judy W.M. Cheng; Vincent Colucci; James S. Kalus; Sarah A. Spinler

doi:10.1177/1060028020934001

Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease

Judy W.M. Cheng
, Vincent Colucci
, James S. Kalus
, Sarah A. Spinler

Pharmacy Practice

Massachusetts College of Pharmacy and Health Sciences
Brigham and Women’s Hospital
Henry Ford Health System
State University of New York Binghamton University

Research output: Contribution to journal › Comment/debate

Abstract

Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection.

Original language	English
Pages (from-to)	252-260
Number of pages	9
Journal	Annals of Pharmacotherapy
Volume	55
Issue number	2
DOIs	https://doi.org/10.1177/1060028020934001
State	Published - Feb 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

chronic kidney disease
diabetes
heart failure
sodium-glucose cotransporter 2 inhibitors

Access to Document

10.1177/1060028020934001

Cite this

@article{2f3d481134434ec59884b76c19f0c496,

title = "Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease",

abstract = "Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection.",

keywords = "chronic kidney disease, diabetes, heart failure, sodium-glucose cotransporter 2 inhibitors",

author = "Cheng, \{Judy W.M.\} and Vincent Colucci and Kalus, \{James S.\} and Spinler, \{Sarah A.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2021",

month = feb,

doi = "10.1177/1060028020934001",

language = "English",

volume = "55",

pages = "252--260",

journal = "Annals of Pharmacotherapy",

issn = "1060-0280",

publisher = "SAGE Publications Inc.",

number = "2",

}

TY - JOUR

T1 - Focused Updates

T2 - SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease

AU - Cheng, Judy W.M.

AU - Colucci, Vincent

AU - Kalus, James S.

AU - Spinler, Sarah A.

N1 - Publisher Copyright: © The Author(s) 2020.

PY - 2021/2

Y1 - 2021/2

N2 - Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection.

AB - Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection.

KW - chronic kidney disease

KW - diabetes

KW - heart failure

KW - sodium-glucose cotransporter 2 inhibitors

UR - https://www.scopus.com/pages/publications/85086372732

U2 - 10.1177/1060028020934001

DO - 10.1177/1060028020934001

M3 - Comment/debate

C2 - 32536199

AN - SCOPUS:85086372732

SN - 1060-0280

VL - 55

SP - 252

EP - 260

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

IS - 2

ER -

Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this